2024 — HERVs as therapeutic targets in neurodegenerative disorders (review)
One-paragraph summary
Review of HERV-targeted therapeutic approaches in neurodegenerative disease. Includes summary of temelimab (anti-HERV-W ENV mAb) clinical-development status (MS Phase 2; long-COVID studies underway via GeNeuro), antiretroviral repurposing strategies (NRTIs in MS), and broader HERV-targeted concept space. Bridging-tier paper providing context for the project's cure-path arm and validating that HERV-as-therapeutic-target is a recognized clinical-development direction.
Claims as triples
- HERV_W_ENV — bridges → temelimab [evidence: review; confidence: bridging]
Methods note
Narrative review.
Limitations
- Narrative; selection bias possible.
- Neurodegenerative disorders specifically; FM-direct relevance is by extension.
Triangulation notes
- Confirms temelimab development is active and HERV-targeted therapy is a recognized clinical-development category.
- Useful for the GeNeuro outreach communications (cure-path arm).